GNRS 591 Midterm Study Guide Exam
Questions With Correct Answers
A |pap |is |done |to |evaluate:
A. |Uterine/Endometrial |cells
B. |Cervical |Cells
C. |Ovarian |Epithelial |Cells
D. |All |of |the |above
B. |Cervical |Cells
The |Gardasil |HPV |vaccine |is |recommended |for:
A. |Females |ages |9 |to |26 |to |protect |against |cervical |cancer-causing |HPV |strains |16 |& |18 |only
B. |Males |and |females |to |protect |against |HPV |strains |16 |and |18 |only
C. |Males |and |females |ages |16 |to |26 |to |protect |against |HPV |strains |6, |11, |16 |& |18
D. |Males |and |females |ages |9 |to |26 |years |to |protect |against |several |HPV |strains |that |can |cause |
cervical |cancer |and |genital |warts
D. |Males |and |females |ages |9 |to |26 |years |to |protect |against |several |HPV |strains |that |can |cause |
cervical |cancer |and |genital |warts
The |pap |result |most |likely |to |be |associated |with |a |CIN |3 |biopsy |result |is:
A. |LSIL
B. |AS-CUS
C. |HSIL
D. |Negative |for |intraepithelial |lesions
C. |HSIL
A |woman |should |be |directed |to |get |her |first |pap |screening:
A. |At |25 |regardless |of |relationship |status
B. |Within |the |first |three |years |of |having |sex |for |the |first |time
C. |10 |years |after |menarche
D. |at |age |21
D. |at |age |21
,A |risk |factor |for |cervical |cancer |is:
A. |BMI |less |than |25
B. |Presence |of |human |papilloma |virus
C. |History |of |chlamydia |10 |years |ago
D. |Nulliparity |(no |history |of |births)
B. |Presence |of |human |papilloma |virus
Appropriate |follow-up |for |a |woman |with |a |pap |result |of |HSIL |and |positive |HPV |is:
A. |Colposcopy
B. |Repeat |pap |in |2 |years
C. |Repeat |pap |in |1 |year
D. |Send |vaginal |culture |to |test |for |gonorrhea |and |chlamydia
A. |Colposcopy
The |Centers |for |Disease |Control |and |Prevention |(CDC) |recommends |human |papillomavirus |
(HPV) |vaccination |for |individuals |in |which |age |group?
A. |9 |to |26 |years |old
B. |9 |to |36 |years |old
C. |11 |to |29 |years |old
D. |16 |to |26 |years |old
A. |9 |to |26 |years |old
Cervical |cancer |screening |recommendations |for |women |ages |30 |and |above |are:
A. |Annual |Pap |smear |test |or |Pap |test |every |three |years |with |HPV |DNA |test
B. |Pap |smear |test |every |three |years |or |Pap |smear |test |plus |HPV |DNA |every |five |years
C. |Pap |smear |test |every |5 |years
D. |Pap |smear |test |with |GC/CT |test |annually
B. |Pap |smear |test |every |three |years |or |Pap |smear |test |plus |HPV |DNA |every |five |years
The |recommended |HPV |vaccine |schedule |is:
A. |Day |1, |2 |months |and |six |months |from |day |one
B. |Day |1, |three |months |and |9 |months |from |day |one
,C. |All |3 |doses |given |within |2 |months |of |each |other
D. |Day |1, |year |one, |and |year |two |from |day |one
A. |Day |1, |2 |months |and |six |months |from |day |one
Women |ages |20 |to |39 |should |receive |a |clinical |breast |exam:
A. |annually
B. |not |unless |they |are |symptomatic
C. |every |five |years |unless |high |risk |factors
D. |at |least |every |three |years |unless |high |risk |factors
D. |at |least |every |three |years |unless |high |risk |factors
Treatment |for |bacterial |vaginosis |includes:
A. |Azithromycin |(Zithromax)
B. |Ceftriaxone |(Rocephin)
C. |Metronidazole |(Flagyl)
D. |Fluconazole |(Diflucan)
C. |Metronidazole |(Flagyl)
Which |patient |should |be |treated |with |ceftriaxone |(Rocephin) |and |doxycycline |(Vibramycin)?
A. |A |pregnant |patient |with |gonorrhea |and |a |yeast |infection
B. |A |non-pregnant |patient |with |gonorrhea |and |chlamydia
C. |A |pregnant |patient |with |syphilis
D. |A |non-pregnant |patient |with |chlamydia |and |trichamoniasis
B. |A |non-pregnant |patient |with |gonorrhea |and |chlamydia
A |patient |comes |to |the |clinic |complaining |of |difficulty |urinating, |flu-like |symptoms, |genital |
tingling, |and |blister-like |vesicles |on |the |upper |thigh |and |vagina. |She |denies |having |ever |had |
these |symptoms |before. |Which |medication |will |you |order |for |the |condition?
A. |Acyclovir |(Zovirax)
B. |Ceftriaxone |(Rocephin)
C. |Penicillin |(Bicillin)
D. |Fluconazole |(Diflucan)
A. |Acyclovir |(Zovirax)
, The |nurse |is |gathering |a |history |from |a |patient |who |is |concerned |she |may |have |a |sexually |
transmitted |infection. |The |woman |describes |having |greenish, |bubbly |discharge |with |a |strong |
odor |and |vaginal |irritation. |Which |lab |test |will |you |use |to |screen |for |the |STI |that |this |woman |
likely |has?
A. |Urine |GC/CT
B. |Pap |smear
C. |Wet |mount |saline |slide
D. |RPR |or |VDRL
C. |Wet |mount |saline |slide
Treatment |options |for |patients |with |condyloma |acuminatum |include:
A. |Imiquimod |(Aldara)
B. |Azithromycin |(Zithromax)
C. |Acyclovir |(Zovirax)
D. |Metrodinazole |(Flagyl)
A. |Imiquimod |(Aldara)
Upon |examination, |the |NP |notes |a |painless |penile |chancre |the |patient |reports |he |noticed |a |
week |ago |along |with |flu-like |symptoms. |The |NP |will |order |which |initial |test |to |screen |for |the |
suspected |condition?
A. |HSV |culture
B. |RPR |or |VDRL
C. |FTA-ABS
D. |Western |blot
B. |RPR |or |VDRL
The |patient |complains |of |vaginal |irritation |and |itching |with |a |thick, |adherent, |white, |cottage-
cheese-like |discharge |for |several |days. |Which |test |would |the |NP |perform |to |help |diagnose |the |
suspected |condition?
A. |Potassium |hydroxide |(KOH) |wet |mount |microscopy
B. |Urine |GC/CT
C. |Colposcopy
D. |FTA-ABS
A. |Potassium |hydroxide |(KOH) |wet |mount |microscopy
Questions With Correct Answers
A |pap |is |done |to |evaluate:
A. |Uterine/Endometrial |cells
B. |Cervical |Cells
C. |Ovarian |Epithelial |Cells
D. |All |of |the |above
B. |Cervical |Cells
The |Gardasil |HPV |vaccine |is |recommended |for:
A. |Females |ages |9 |to |26 |to |protect |against |cervical |cancer-causing |HPV |strains |16 |& |18 |only
B. |Males |and |females |to |protect |against |HPV |strains |16 |and |18 |only
C. |Males |and |females |ages |16 |to |26 |to |protect |against |HPV |strains |6, |11, |16 |& |18
D. |Males |and |females |ages |9 |to |26 |years |to |protect |against |several |HPV |strains |that |can |cause |
cervical |cancer |and |genital |warts
D. |Males |and |females |ages |9 |to |26 |years |to |protect |against |several |HPV |strains |that |can |cause |
cervical |cancer |and |genital |warts
The |pap |result |most |likely |to |be |associated |with |a |CIN |3 |biopsy |result |is:
A. |LSIL
B. |AS-CUS
C. |HSIL
D. |Negative |for |intraepithelial |lesions
C. |HSIL
A |woman |should |be |directed |to |get |her |first |pap |screening:
A. |At |25 |regardless |of |relationship |status
B. |Within |the |first |three |years |of |having |sex |for |the |first |time
C. |10 |years |after |menarche
D. |at |age |21
D. |at |age |21
,A |risk |factor |for |cervical |cancer |is:
A. |BMI |less |than |25
B. |Presence |of |human |papilloma |virus
C. |History |of |chlamydia |10 |years |ago
D. |Nulliparity |(no |history |of |births)
B. |Presence |of |human |papilloma |virus
Appropriate |follow-up |for |a |woman |with |a |pap |result |of |HSIL |and |positive |HPV |is:
A. |Colposcopy
B. |Repeat |pap |in |2 |years
C. |Repeat |pap |in |1 |year
D. |Send |vaginal |culture |to |test |for |gonorrhea |and |chlamydia
A. |Colposcopy
The |Centers |for |Disease |Control |and |Prevention |(CDC) |recommends |human |papillomavirus |
(HPV) |vaccination |for |individuals |in |which |age |group?
A. |9 |to |26 |years |old
B. |9 |to |36 |years |old
C. |11 |to |29 |years |old
D. |16 |to |26 |years |old
A. |9 |to |26 |years |old
Cervical |cancer |screening |recommendations |for |women |ages |30 |and |above |are:
A. |Annual |Pap |smear |test |or |Pap |test |every |three |years |with |HPV |DNA |test
B. |Pap |smear |test |every |three |years |or |Pap |smear |test |plus |HPV |DNA |every |five |years
C. |Pap |smear |test |every |5 |years
D. |Pap |smear |test |with |GC/CT |test |annually
B. |Pap |smear |test |every |three |years |or |Pap |smear |test |plus |HPV |DNA |every |five |years
The |recommended |HPV |vaccine |schedule |is:
A. |Day |1, |2 |months |and |six |months |from |day |one
B. |Day |1, |three |months |and |9 |months |from |day |one
,C. |All |3 |doses |given |within |2 |months |of |each |other
D. |Day |1, |year |one, |and |year |two |from |day |one
A. |Day |1, |2 |months |and |six |months |from |day |one
Women |ages |20 |to |39 |should |receive |a |clinical |breast |exam:
A. |annually
B. |not |unless |they |are |symptomatic
C. |every |five |years |unless |high |risk |factors
D. |at |least |every |three |years |unless |high |risk |factors
D. |at |least |every |three |years |unless |high |risk |factors
Treatment |for |bacterial |vaginosis |includes:
A. |Azithromycin |(Zithromax)
B. |Ceftriaxone |(Rocephin)
C. |Metronidazole |(Flagyl)
D. |Fluconazole |(Diflucan)
C. |Metronidazole |(Flagyl)
Which |patient |should |be |treated |with |ceftriaxone |(Rocephin) |and |doxycycline |(Vibramycin)?
A. |A |pregnant |patient |with |gonorrhea |and |a |yeast |infection
B. |A |non-pregnant |patient |with |gonorrhea |and |chlamydia
C. |A |pregnant |patient |with |syphilis
D. |A |non-pregnant |patient |with |chlamydia |and |trichamoniasis
B. |A |non-pregnant |patient |with |gonorrhea |and |chlamydia
A |patient |comes |to |the |clinic |complaining |of |difficulty |urinating, |flu-like |symptoms, |genital |
tingling, |and |blister-like |vesicles |on |the |upper |thigh |and |vagina. |She |denies |having |ever |had |
these |symptoms |before. |Which |medication |will |you |order |for |the |condition?
A. |Acyclovir |(Zovirax)
B. |Ceftriaxone |(Rocephin)
C. |Penicillin |(Bicillin)
D. |Fluconazole |(Diflucan)
A. |Acyclovir |(Zovirax)
, The |nurse |is |gathering |a |history |from |a |patient |who |is |concerned |she |may |have |a |sexually |
transmitted |infection. |The |woman |describes |having |greenish, |bubbly |discharge |with |a |strong |
odor |and |vaginal |irritation. |Which |lab |test |will |you |use |to |screen |for |the |STI |that |this |woman |
likely |has?
A. |Urine |GC/CT
B. |Pap |smear
C. |Wet |mount |saline |slide
D. |RPR |or |VDRL
C. |Wet |mount |saline |slide
Treatment |options |for |patients |with |condyloma |acuminatum |include:
A. |Imiquimod |(Aldara)
B. |Azithromycin |(Zithromax)
C. |Acyclovir |(Zovirax)
D. |Metrodinazole |(Flagyl)
A. |Imiquimod |(Aldara)
Upon |examination, |the |NP |notes |a |painless |penile |chancre |the |patient |reports |he |noticed |a |
week |ago |along |with |flu-like |symptoms. |The |NP |will |order |which |initial |test |to |screen |for |the |
suspected |condition?
A. |HSV |culture
B. |RPR |or |VDRL
C. |FTA-ABS
D. |Western |blot
B. |RPR |or |VDRL
The |patient |complains |of |vaginal |irritation |and |itching |with |a |thick, |adherent, |white, |cottage-
cheese-like |discharge |for |several |days. |Which |test |would |the |NP |perform |to |help |diagnose |the |
suspected |condition?
A. |Potassium |hydroxide |(KOH) |wet |mount |microscopy
B. |Urine |GC/CT
C. |Colposcopy
D. |FTA-ABS
A. |Potassium |hydroxide |(KOH) |wet |mount |microscopy
